Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview.
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade.
Genzyme’s once-daily, oral AUBAGIO® (teriflunomide) approved in Argentina for the treatment of relapsing multiple sclerosis
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
Sleep and Cognitive Function in Multiple Sclerosis.
Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Neuromyelitis optica spectrum disorder (NMOSD): A new concept.
Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study.
Intrathecal interferon reduces exacerbations of multiple sclerosis.
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Clarity Extension Study
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
The "poison chair" treatment for multiple sclerosis.
Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Effect of vitamin D on MS activity by disease-modifying therapy class.
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.
Mast cell inflammasome activity in the meninges regulates EAE disease severity.

Pages